Trevi Therapeutics (TRVI) Cash & Equivalents (2018 - 2026)

Trevi Therapeutics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $19.4 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents changed 0.2% year-over-year to $19.4 million in Q1 2026; TTM through Mar 2026 was $19.4 million, a 0.2% change from a year earlier, with the FY2025 full-year figure at $18.9 million, down 44.53% from the prior year.
• Cash & Equivalents grew to $19.4 million in Q1 2026 per TRVI's latest filing, from $18.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $117.1 million in Q2 2025 and bottomed at $11.6 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $19.4 million (2025), against an average of $29.9 million.
• Across the five-year window, Cash & Equivalents tumbled 72.12% in 2022 and jumped 803.02% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $12.6 million in 2022, then jumped by 157.34% to $32.4 million in 2023, then increased by 5.25% to $34.1 million in 2024, then slumped by 44.53% to $18.9 million in 2025, then increased by 2.63% to $19.4 million in 2026.
• Per Business Quant, the three latest TRVI Cash & Equivalents figures stand at $19.4 million (Q1 2026), $18.9 million (Q4 2025), and $56.9 million (Q3 2025).